Results 41 to 50 of about 3,850,355 (295)
Epigenetically inactivated RASSF1A as a tumor biomarker
Bosnian Journal of Basic Medical Sciences, 2020 RASSF1A represents one of the eight isoforms of the RASSF1 gene. RASSF1A is a tumor suppressor gene whose inactivation influences tumor initiation and development. In cancer, RASSF1A is frequently inactivated by mutations, loss of heterozygosity and, most commonly, by promoter hypermethylation.
Dora Raos +5 more
openaire +7 more sources
Breast fine-needle aspiration cytology in the era of core-needle biopsy: what is its role? [PDF]
Journal of Pathology and Translational MedicineFine-needle aspiration cytology (FNAC) has long been recognized as a minimally invasive, cost-effective, and reliable diagnostic tool for breast lesions.
Ahrong Kim, Hyun Jung Lee, Jee Yeon Kim
doaj +1 more source
The association between CTSZ methylation in peripheral blood and breast cancer in Chinese women
Frontiers in Oncology, 2023 PurposePrevious studies have shown that DNA methylation in peripheral blood may be associated with breast cancer (BC). To explore the association between the methylation level of the Cathepsin Z (CTSZ) gene in peripheral blood and BC, we conducted a case–
Jinyu Li +18 more
doaj +1 more source
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Signal Transduction and Targeted TherapyTumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction,
Yuee Zhou +9 more
semanticscholar +1 more source
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
JCI Insight, 2019 BACKGROUND PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy.
M. Yarchoan +10 more
semanticscholar +1 more source
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors [PDF]
Cancer Discovery, 2020 AbstractTumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing–based estimates of TMB have largely replaced whole-exome sequencing–derived TMB in the clinic.
Dan Sha +5 more
openaire +3 more sources
Frontiers in ImmunologyBackgroundEarly diagnosis of lung cancer is crucial for improving patient outcomes. Autoantibodies against tumor-associated antigens (TAAs) found in the plasma can serve as biomarkers for lung cancer detection.
Xiaobin Cao +14 more
doaj +1 more source
Aberrant Expression and Prognostic Potential of IL-37 in Human Lung Adenocarcinoma
Biomedicines, 2022 Interleukin-37 (IL-37) is a relatively new IL-1 family cytokine that, due to its immunoregulatory properties, has lately gained increasing attention in basic and translational biomedical research.
Panayiota Christodoulou +7 more
doaj +1 more source
Biomarkers for patients with Wilms tumor: a review
Frontiers in Oncology, 2023 Wilms tumor, originating from aberrant fetal nephrogenesis, is the most common renal malignancy in childhood. The overall survival of children is approximately 90%. Although existing risk-stratification systems are helpful in identifying patients with poor prognosis, the recurrence rate of Wilms tumors remains as high as 15%.
Hongfeng Zheng +3 more
openaire +3 more sources
Lipid-loaded macrophages as new therapeutic target in cancer
Journal for ImmunoTherapy of Cancer, 2022 Macrophages are main players of the innate immune system. They show great heterogeneity and play diverse functions that include support to development, sustenance of tissue homeostasis and defense against infections.
Ping-Chih Ho +7 more
doaj +1 more source